Trials / Recruiting
RecruitingNCT07368803
Evaluation of the Safety, Tolerability and Efficacy of iNeo-Vac-R01, an Individualized mRNA Therapeutic Technology Based on Tumor Neoantigens, for Adjuvant Treatment in Patients With Biliary Malignant Tumors After Radical Resection
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Yifan Wang · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety of iNeo-Vac-R01, an individualized mRNA therapeutic technology based on tumor neoantigens, for the adjuvant treatment of patients with biliary malignant tumors after radical resection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | iNeo-Vac-R01 | IH injection |
Timeline
- Start date
- 2025-09-11
- Primary completion
- 2027-09-30
- Completion
- 2027-09-30
- First posted
- 2026-01-27
- Last updated
- 2026-02-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07368803. Inclusion in this directory is not an endorsement.